whitepaper
Whitepaper: Recombinant protein expression using a BEVS
In this article, Sino Biological highlight the importance of recombinant protein expression using a baculovirus-insect cell system (BEVS) and application of BEVS.
List view / Grid view
Antibodies
webinar
Assays for protein degradation therapeutics to accelerate undruggable proteome discoveries
9 May 2022 | By PerkinElmer and C4
Looking for a way to address the undruggable proteins in the human body? Watch this free on-demand webinar where industry experts discuss strategies to accelerate TPD drug discovery efforts using high-throughput cell-based assays.
whitepaper
Infographic: Overview of the CAR-T cell therapy workflow
Find out more about the CAR-T cell therapy workflow in this informative infographic from Bio-Rad Laboratories (CA, USA). Discover some of the challenges associated with CAR-T cell R&D as well as technologies and reagents used for bioanalytical analysis.
news
The power of T-cell immune response to Omicron variants
In a new study, researchers have demonstrated the efficiency of T-cell immune response against the Omicron variant of SARS-CoV-2.
article
Cell line development tactics and strategies for faster Investigational New Drug timelines
Complexities related to the development of stable cell lines and increased risk of contamination in upstream and downstream processes, have led many developers to seek critically needed expertise from external partners. Soojin Han, Samsung Biologics America, offers an expert look at the various challenges and tactics that can be applied.
news
A machine learning model that could identify antibody targets
Using a machine learning model, scientists could predict not only the virus an antibody will attack, but which features on the pathogen the antibody binds to.
video
Video: Anti-Idiotypic antibodies for development of CAR T cell therapies
Interview with Michael Schwenkert, Bio-Rad Laboratories, on best practices for the characterisation and quality control of anti-idiotypic antibodies for bioanalysis.
news
Biodegradable gel boosts immune system’s attack on several cancers in mice
A new biodegradable gel can release drugs and special antibodies that simultaneously deplete macrophages from the surgical site and activate T cells.
news
COVID vaccine that could protect against Omicron and other variants
The antigen-based vaccine has the potential to induce sterilising immunity to old and new SARS-CoV-2 variants by preventing infection by stopping viral replication and transmission through the inhibition of cellular virus entry.
podcasts
Episode 7 – Cell line development with Dr Natasa Skoko, ICGEB & Dr Hugh Graham, MacroGenics
Tune in to this podcast to hear industry experts discuss cell line monoclonality and the emerging methods that can support clonal origin assurance.
news
VBI Vaccines announces progress from coronavirus programme
Pre-clinical research from VBI Vaccines has demonstrated an encouraging ability to boost and broaden the immune response against the coronavirus Beta variant.
article
Viewing disease through the lens of memory B cells: improving cancer and infectious disease treatment
Looking at disease through a patient’s memory B cells can reveal vulnerabilities within pathogens. In this article, Dr Purnanand Sarma, President and Chief Executive Officer of Immunome, explores how advancements in memory B-cell antibody-based treatments will improve our understanding of how these cells can aid in fighting cancer and other diseases.
article
Neutralising SARS-CoV-2 with intranasally-delivered antibodies
A monoclonal antibody (mAb) developed by IGM Biosciences to combat COVID-19 has shown success in pre-clinical studies and has now moved into Phase I trials. In this Q&A, Dr Chris Takimoto, Chief Medical Officer at IGM Biosciences, explains how this biotherapeutic works to prevent and treat SARS-CoV-2 infection.
article
Emerging trends in biotherapeutic development
The COVID-19 pandemic has placed a spotlight on the discovery and development of biotherapeutics, for both the treatment and prevention of diseases. In this article, industry experts discuss the emerging trends they see in biotherapeutic development and how they predict the field will evolve in the near future.
article
How to develop the next generation of CAR T-cell therapies
CAR T cells have shown incredible promise in the clinic, but there is still room for advancement. One avenue for improvement is through modification of the CAR design. However, given the number of exchangeable domains, testing all variations can present a hurdle. In this article, Dr Sarwish Rafiq, Assistant Professor in…